LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling

While the antiandrogen enzalutamide (Enz) extends the castration resistant prostate cancer (CRPC) patients’ survival an extra 4.8 months, it might also result in some adverse effects via inducing the neuroendocrine differentiation (NED). Here we found that lncRNA-p21 is highly expressed in the NEPC...

詳細記述

保存先:
書誌詳細
出版年:Nat Commun
主要な著者: Luo, Jie, Wang, Keliang, Yeh, Shuyuan, Sun, Yin, Liang, Liang, Xiao, Yao, Xu, Wanhai, Niu, Yuanjie, Cheng, Liang, Maity, Sankar N., Jiang, Runze, Chang, Chawnshang
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group UK 2019
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6561926/
https://ncbi.nlm.nih.gov/pubmed/31189930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-09784-9
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料